(RTTNews) - AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of late-stage pancreatic cancer. The combination therapy was generally well-tolerated with no severe adverse events or dose-limiting toxicities. The first cohort has now reached the pre-determined 6-month stability assessment timepoint and two of the three subjects remain stable.
AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The company's lead product is a first-in-class investigational drug called Ampligen.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
